Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective

Objectives: The results of a CHOICE-1 study demonstrated the superior efficacy of toripalimab (anti-PD-1 antibody) plus chemotherapy for patients with advanced non–small cell lung cancer (NSCLC), with a manageable safety profile. This study was performed to evaluate the economic value of this treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Kexun, Shu, Pei, Zheng, Hanrui, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229795/
https://www.ncbi.nlm.nih.gov/pubmed/37266153
http://dx.doi.org/10.3389/fphar.2023.1133085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229795/
https://www.ncbi.nlm.nih.gov/pubmed/37266153
http://dx.doi.org/10.3389/fphar.2023.1133085

Ejemplares similares